Semax Price

Peptide Price Index 2026: 90-Day Vendor Trends | The Peptide Catalog

thepeptidecatalog.com

30–60% CoV: 5-amino-1MQ (30.5%), semax (30.4%). Related industry context: FDA Peptide Reclassification Timeline · Peptide Vendor Shutdowns 2025-2026 ·

Semax Peptide | ≥99% Pure | Nationwide Peptides

www.nationwidepeptides.com

Functional Med Doc (2025) Semax therapeutic [https://functionalmeddoc.com/common-conditions/semax-peptide/]. Research-grade Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of ACTH(4-10) designed for controlled laboratory investigations of BDNF expression, neuroprotection, and ischemia pathway research models. For Research Use Only. Semax is a synthetic heptapeptide developed at the Institute of Molecular Genetics, Russian Academy of Sciences, in the 1980s. It mimics the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10) but lacks hormonal activity. It has been studied in scientific literature for its interactions with BDNF synthesis, serotonin/dopamine systems, and gene expression related to vascular and immune pathways. Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH) fragments.

Where to Buy Semax: Price & Vendor Guide (2026) | The Peptide Catalog

thepeptidecatalog.com

Semax is the synthetic ACTH(4-7) analog with extensive Russian clinical use as a stroke recovery agent and cognitive nootropic. The published research base includes a clinical study of semax in ischemic stroke patients (Gusev et al. 2018) and pre-clinical work on BDNF/TrkB modulation in the rat hippocampus (Dolotov et al. Research-context information only. Semax is a research peptide approved in Russia as a finished pharmaceutical product but not FDA-approved in the United States. Protocols, doses, and reactions reported below come from published research (mostly Russian) and self-reported community sources. Key insight: Pre-mixed nasal sprays are 4-7x cheaper per dose than lyophilized vials at the same daily dose. This is unusual — most peptides have lyophilized as the cheaper format. For semax, the spray dominance is driven by direct manufacturer-to-user spray packaging at high volume. The buying problem is unique to semax: most users administer it intranasally, so pre-mixed nasal sprays are the dominant format.

Peptide Therapeutics Market Size & Trends Report 2031

www.mordorintelligence.com

Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of January 2026. ... Oncology and metabolic disorders increasingly share a therapeutic toolbox, as peptide receptor radionuclide therapy and GLP-1 agonists demonstrate disease-modifying potential across both areas. FDA approval of elamipretide for Barth syndrome and ongoing expansion of PRRT validate peptides in rare cancers where small molecules lack specificity[1]U.S. FDA, “47 Peptide Candidates Granted Orphan Status in 2024,” fda.gov. The peptide therapeutics market for branded peptides in 2025 represented a 61.55% share. Branded incumbents defend position through lifecycle strategies such as Novo Nordisk’s TransCon Semaglutide collaboration and Roche’s acquisition of petrelintide rights. Generic formulations, however, are projected to grow at an 8.25% CAGR from 2026 to 2031, buoyed by the FDA approval of generic liraglutide and a pipeline of ANDAs for exenatide and dulaglutide. The FDA scheduled a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to evaluate seven peptide bulk drug substances for potential inclusion on the 503A list, which reinforces the importance of clear regulatory positioning between compounded supply and approved peptide drug pathways. The top originators, Eli Lilly, Bristol-Myers Squibb Company, and others, controlled a significant percentage of global revenue in 2025, indicating moderate concentration. June 2026: Hanmi Pharmaceutical announced an exclusive license agreement with Eli Lilly and Company covering development, manufacturing, and commercialization of sonefpeglutide (a long-acting GLP-2 analog) worldwide excluding Korea. The deal strengthens big-pharma access to differentiated, long-acting peptide assets in gastrointestinal indications where dosing convenience and manufacturing scalability are central to uptake. December 2025: Eli Lilly announced a USD 6 billion investment to build a new active pharmaceutical ingredient manufacturing facility in Huntsville, Alabama.

Peptide Therapeutics Market Size 2035

www.rootsanalysis.com

The peptide therapeutics market, valued at USD 90.2 billion in 2025, is projected to reach USD 108.2 billion in 2026 and USD 233.6 billion by 2035, representing a CAGR of 8.9% during the forecast period 2026 to 2035. Importantly, peptides accounted for approximately 10% of all new FDA drug approvals between 2020 and 2024, reflecting their growing importance within the pharmaceutical industry. As a result, pharmaceutical companies continue to invest in peptide engineering, drug delivery technologies, and manufacturing infrastructure. These investments are intended to improve therapeutic performance and meet growing market demand. For instance, in December 2025, Eli Lilly announced multibillion-dollar investments in new manufacturing facilities to expand peptide production capacity and strengthen supply chain resilience. In March 2026, Johnson & Johnson, in collaboration with Protagonist Therapeutics, received FDA approval for ICOTYDE (icotrokinra), the first targeted oral peptide IL-23 receptor antagonist for the treatment of moderate-to-severe plaque psoriasis. In February 2026, Zonsen PepLib Biotech entered into a global research collaboration and licensing agreement with Eli Lilly to discover and develop novel peptide therapeutics using PepLib's proprietary peptide library platform.

Where to Buy Semax in 2026: Best Sources, Pricing & What to Look ...

www.peptidedeck.com

Where to buy Semax in 2026 without getting burned: vendor checks, lyophilized vs nasal spray, NA Semax vs standard Semax, fair pricing, and the best source for verified third-party tested vials. ... Explore research peptides from Synthro Lab. USA manufacturing, 99% tested purity, free express shipping over $150. Buy 1 Get 1 Free.Shop Peptides at Synthro Lab ... Searching "where to buy Semax" returns dozens of vendors selling nasal sprays, lyophilized vials, and questionable "research blends" in equal measure. This guide is for the buyer who already knows roughly what Semax does and now wants the practical buying side: who actually sells it, what to demand from a vendor, and what to skip. For mechanism, dosing protocols, and effects, see the Semax overview and Semax benefits guide first. Short answer: Ascension Peptides is the cleanest option for Semax in 2026. The COA should come from an independent lab, not the manufacturer's own testing, and confirm peptide purity (≥98%), correct molecular weight, and absence of common contaminants. If a vendor can't produce one, walk away. Two compounds get sold as "Semax": standard Semax (Met-Glu-His-Phe-Pro-Gly-Pro) and N-acetyl Semax Amidate (NA Semax).